The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to deliver a more substantial loss in